Pharma & Biotech
一次情報からAIが生成する週次リサーチレポート。 · 16 reports
Pharma & Biotech
The week of August 3–10, 2026 was defined by a cluster of landmark FDA approvals — most notably Moderna's first mRNA flu vaccine and Takeda's first orexin drug for narcolepsy — alongside intensifying …
Pharma & Biotech
The final week of July 2026 and the start of August brought a dense cluster of clinical, regulatory, and corporate developments across pharma and biotech. J&J extended its oncology dominance through a…
Pharma & Biotech
July 2026 was a landmark month for pharma and biotech, defined by a surging XBI at five-year highs, an accelerating M&A supercycle exceeding 45 first-half acquisitions, and AI companies crossing from …
Pharma & Biotech
Week 4 of July 2026 was defined by J&J's dual breakthrough — OTTAVA robotic surgical system FDA authorization and landmark MonumenTAL-6 Phase 3 myeloma data — alongside the GLP-1 market's escalation t…
Pharma & Biotech
Week 3 of July 2026 was defined by two landmark approvals — Merck's first oral PCSK9 inhibitor and J&J's strong quarterly results — alongside Eli Lilly's $2.8 billion psychedelics acquisition, escalat…
Pharma & Biotech
Week 2 of July 2026 saw pharma's M&A wave reach 45+ first-half deals, Vertex's landmark $10B Crinetics acquisition, multiple KEYTRUDA approvals, government-backed gene editing investment, and enacted …
Pharma & Biotech
The first week of July 2026 saw the biotech sector hit a five-year high with XBI up 30% YTD, Anthropic enter drug development directly, Roche establish head-to-head superiority in KRAS-driven lung can…
Pharma & Biotech
June 2026 was defined by a historic wave of oncology data at ASCO, record-breaking pharma M&A activity reaching $134 billion in H1 2026, and intensifying geopolitical pressure on pharmaceutical pricin…
Pharma & Biotech
The final weeks of June 2026 brought a record-pace pharma M&A surge ($134 billion in H1 2026), a wave of new regulatory milestones including EMA CHMP recommendations and FDA approvals, and intensifyin…
Pharma & Biotech
The G7 Summit concluded with a landmark first-ever cancer declaration and industry mobilization around the Ebola Bundibugyo outbreak intensified, with named companies advancing therapeutics and vaccin…
Pharma & Biotech
The mid-June 2026 pharma and biotech landscape is marked by J&J's expansion of its nipocalimab autoimmune franchise with pivotal wAIHA data and acquisition of Firefly Bio for oncology pipeline strengt…
Pharma & Biotech
The early June 2026 pharma and biotech landscape is defined by new autoimmune and metabolic pipeline breakthroughs — including J&J's nipocalimab Phase 2 SLE data and Pfizer's monthly-dosed GLP-1 berob…
Pharma & Biotech
ASCO 2026 dominated the late May 2026 pharma reporting period, with J&J, Pfizer, and Revolution Medicines delivering practice-changing oncology data across multiple tumor types, while Japan's declinin…
Pharma & Biotech
The May 2026 pharma and biotech landscape is defined by EMA's recommendation of eight new medicines, widening EU medicine access inequality per EFPIA's WAIT report, and coordinated global policy actio…
Pharma & Biotech
The pharma and biotech landscape in mid-May 2026 is marked by deepening FDA leadership upheaval — with both the Commissioner and CDER chief now departed — alongside the finalization of the EU Critical…
Pharma & Biotech
This baseline report covers the pharma and biotech sector in mid-2026, highlighting AI-driven drug discovery advances, major regulatory shifts including FDA leadership instability, landmark EU legisla…